BeOne Medicines AG (NASDAQ:ONC) is one of the 10 Best European Growth Stocks to Buy.
On May 15, 2026, Leerink raised the firm’s price target on BeOne Medicines AG (NASDAQ:ONC) to $367 from $364 while maintaining an Outperform rating on the shares. The firm noted that the FDA granted accelerated approval to sonrotoclax for the treatment of relapsed or refractory mantle cell lymphoma. Leerink added that the approval marks the first regulatory approval for sonrotoclax, with additional studies ongoing across multiple hematologic cancer indications, including combinations with zanubrutinib and anti-CD20 antibodies.
On May 13, 2026, BeOne Medicines announced that the U.S. FDA granted accelerated approval to Beqalzi, its next-generation BCL2 inhibitor, for adult patients with relapsed or refractory mantle cell lymphoma following at least two prior lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor. The company said Beqalzi was designed to improve BCL2 inhibition through greater potency, selectivity, and a pharmacologic profile that could potentially improve efficacy, tolerability, and convenience compared to existing therapies in the class. Continued approval for the indication remains contingent on confirmation of clinical benefit in the ongoing CELESTIAL-RRMCL confirmatory trial. The FDA also granted Breakthrough Therapy, Fast Track, and Orphan Drug designations for sonrotoclax in this indication.
create jobs 51/Shutterstock.com
Earlier in May, BeOne Medicines AG (NASDAQ:ONC) reported Q1 adjusted EPS of $3.24, compared to $1.22 in the prior-year quarter. Revenue totaled $1.51B, ahead of the consensus estimate of $1.44B. Co-Founder, Chairman, and CEO John Oyler said the quarter reflected continued growth driven by commercial execution and expanding leadership in hematology, alongside the company’s growing solid tumor pipeline. Oyler also highlighted the continued momentum of BRUKINSA, which management described as a foundational BTK inhibitor with strong long-term efficacy and safety data in chronic lymphocytic leukemia. The company additionally pointed to the combination of sonrotoclax and BRUKINSA as a potential future standard-of-care treatment in first-line CLL.
BeOne Medicines AG (NASDAQ:ONC) develops oncology therapies focused on hematologic cancers and solid tumors across global markets.
While we acknowledge the risk and potential of ONC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ONC and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
